Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Novo Nordisk A/S stock | $73.8

Own Novo Nordisk A/S stock in just a few minutes.

Fact checked

Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 44,326 staff and has a market cap (total outstanding shares value) of USD$163.1 billion.

How to buy shares in Novo Nordisk A/S

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Novo Nordisk A/S. Find the stock by name or ticker symbol: NVO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novo Nordisk A/S reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$73.8, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Novo Nordisk A/S, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Novo Nordisk A/S. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Novo Nordisk A/S share price

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk A/S shares at a glance

Information last updated 2020-12-30.
Latest market closeUSD$73.8
52-week rangeUSD$48.1852 - USD$73.92
50-day moving average USD$68.6947
200-day moving average USD$67.7388
Wall St. target priceUSD$74.08
PE ratio 28.6678
Dividend yield USD$1.04 (1.47%)
Earnings per share (TTM) USD$2.462

Buy Novo Nordisk A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novo Nordisk A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novo Nordisk A/S price performance over time

Historical closes compared with the close of $73.8 from 2020-12-18

1 week (2021-01-07) 5.29%
1 month (2020-12-17) 2.89%
3 months (2020-10-15) 4.58%
6 months (2020-07-15) 10.83%
1 year (2020-01-15) 18.29%
2 years (2019-01-15) 56.36%
3 years (2018-01-13) N/A
5 years (2016-01-15) 38.93%

Is Novo Nordisk A/S under- or over-valued?

Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk A/S's P/E ratio

Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Novo Nordisk A/S shares trade at around 29x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk A/S's PEG ratio

Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.8731. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novo Nordisk A/S financials

Gross profit TTM USD$102.5 billion
Return on assets TTM 26.33%
Return on equity TTM 73.83%
Profit margin 32.65%
Book value $3.077
Market capitalisation USD$163.1 billion

TTM: trailing 12 months

Shorting Novo Nordisk A/S shares

There are currently 4.1 million Novo Nordisk A/S shares held short by investors – that's known as Novo Nordisk A/S's "short interest". This figure is 27.8% down from 5.7 million last month.

There are a few different ways that this level of interest in shorting Novo Nordisk A/S shares can be evaluated.

Novo Nordisk A/S's "short interest ratio" (SIR)

Novo Nordisk A/S's "short interest ratio" (SIR) is the quantity of Novo Nordisk A/S shares currently shorted divided by the average quantity of Novo Nordisk A/S shares traded daily (recently around 995992.70072993). Novo Nordisk A/S's SIR currently stands at 4.11. In other words for every 100,000 Novo Nordisk A/S shares traded daily on the market, roughly 4110 shares are currently held short.

However Novo Nordisk A/S's short interest can also be evaluated against the total number of Novo Nordisk A/S shares, or, against the total number of tradable Novo Nordisk A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novo Nordisk A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Novo Nordisk A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Novo Nordisk A/S shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novo Nordisk A/S.

Find out more about how you can short Novo Nordisk A/S stock.

Novo Nordisk A/S share dividends


Dividend payout ratio: 48.37% of net profits

Recently Novo Nordisk A/S has paid out, on average, around 48.37% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.47% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $1.04 per share.

While Novo Nordisk A/S's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk A/S may be investing much of the rest of its net profits in future growth.

Novo Nordisk A/S's most recent dividend payout was on 25 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2020 (the "ex-dividend date").

Have Novo Nordisk A/S's shares ever split?

Novo Nordisk A/S's shares were split on a 5:1 basis on 9 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.

Novo Nordisk A/S share price volatility

Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $48.1852 up to $73.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.3163. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).

Novo Nordisk A/S overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site